Skip to main content
Download PDF

Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients

BMC Nephrology volume 21, Article number: 227 (2020) Cite this article

Abstract

Background

Acute kidney injury (AKI) occurs in 12–20% of multiple myeloma (MM) patients. Several studies have shown a reduction of free light chains (FLC) using hemodialysis with High-Cut-Off membranes. However, this technique entails albumin loss. Hemodiafiltration with ultrafiltrate regeneration is a technique that includes a process of adsorption. The aim of this study was to evaluate the effectiveness of hemodiafiltration with ultrafiltrate regeneration in reducing FLC levels without causing albumin loss.

Methods

This is an observational study (2012 to 2018) including nine patients with MM (5 kappa, 4 lambda) and AKI. All patients were treated with chemotherapy and hemodiafiltration with ultrafiltrate regeneration. Blood Samples (pre and post-dialysis) and ultrafiltrate were collected pre and post-resin at 5 min after initiation of the session and 5 min before the end of the procedure.

Results

The serum levels of kappa and lambda were reduced by a 57.6 ± 10% and 33.5 ± 25% respectively. Serum albumin concentration remained unchanged after the procedure. In the ultrafiltrate, the mean FLC reduction ratio shortly after initiation of the dialysis procedure was: 99.2 and 97.06% for kappa and lambda respectively, and only 0.7% for albumin; and at the end of the session the percent reduction was: 63.7 and 33.62% for kappa and lambda respectively, and 0.015% for albumin. Patients clinical outcome was: 33.3% recovered renal function, 22.2% died during the first year and 44.4% required maintenance dialysis.

Conclusions

Hemodiafiltration with ultrafiltrate regeneration reduces FLC levels without producing a significant loss of albumin; and, FLC removal is maintained throughout the session. Therefore, hemodiafiltration with ultrafiltrate regeneration may be considered an effective adjunctive therapy in patients with MM.

Peer Review reports

Background

Multiple myeloma (MM) is a malignant plasma cell proliferation characterized by overproduction of monoclonal immunoglobulins. Severe acute kidney failure (AKI) is observed in 12–20% of MM patients and it is produced mainly by deposition of light chains, cast formation and tubular obstruction (myeloma cast nephropathy) [1, 2]. There have been improvements in the management of this disease, however severe renal failure continues to be an important burden that worsens the prognosis [3]; in fact dialysis is required in a 10% of cases [1, 4, 5].

The production of free light chains (FLC) is reduced with the use of chemotherapy (dexamethasone, bortezomib, melphalan, thalidomide, lenalidomide, cyclophosphamide) associated or not to autotransplantation of hematopoietic cells [6]. An adjuvant therapy is the use of extrarenal depuration techniques to reduce the levels of FLC so the kidney damage is minimized. In recent years, several studies have been published on the effectiveness of very high permeability, “High-Cut-Off” (HCO) membranes for the removal of FLC and protein bound uremic toxins [7]. With a sustained reduction of FLC the recovery of kidney function has been reported to be as high as 64% which is associated to better survival [8,9,10,11]. However other authors have not reported a significant difference in renal function recovery between HCO and high flux hemodialysis [12, 13]. An important drawback of procedures using HCO is the abundant loss of albumin requiring continuous replacement [6, 8].

Hemodiafiltration with regeneration of the ultrafiltrate by adsorption using a resin (Supra HFR) has been introduced as an extrarenal clearance technique that combines convection, adsorption and diffusion; it uses a high cut-off “Super High Flux” polyphenylene membrane. We have shown that hemodiafiltration with ultrafiltrate regeneration, may improve uremic protein-bound toxin removal, inflammatory state, endothelial damage, and oxidative stress as compared with on-line hemodiafiltration and high-flux hemodialysis [14]. Since a high cut-off membrane should allow the passage of FLC (especially kappa), without the loss of albumin (molecular weight 60 kD), hemodiafiltration with ultrafiltrate regeneration might be a reasonable strategy for FLC removal [15]. We had explored the feasibility of using hemodiafiltration with ultrafiltrate regeneration in 3 patients with MM and AKI, the results were encouraging and there was no need for albumin replacement [16]. The aim of the present study is to evaluate the effectiveness of hemodiafiltration with ultrafiltrate regeneration in reducing FLC and its effect on albumin in patients with AKI secondary to MM.

Methods

Patients

This is an observational study that includes 9 patients with AKI due to MM diagnosed in our centre between July 2012 and December 2018. All patients were immediately treated with chemotherapy according to Hematology protocol (based on bortezomib and corticosteroids) and hemodiafiltration with ultrafiltrate regeneration was used as renal replacement therapy. All patients with AKI and MM requiring renal replacement treatment were dialyzed with Supra HFR, even if serum FLC were < 500 mg/L, the intention was to maintain FLC levels below this threshold. The main criteria for renal replacement therapy was a decreased glomerular filtration rate (< 7–10 ml/min/1.73m2). The baseline creatinine before diagnosis of MM was normal. The exclusion criteria from the study were cases of relapse MM and those with AKI on a background of chronic kidney disease. All patients were followed until death or censored at 2019 January 31st if remained alive.

The diagnosis of MM was made based on the presence of clonal bone marrow plasma cells (> 10%), serum and/or urinary monoclonal protein and evidence of end organ damage that can be attributed to a plasma cell proliferative disorder [17]. Free light chains removal is useful in myeloma cast nephropathy as reported by several authors [8, 18]. A kidney biopsy was performed in 3 cases that showed myeloma cast nephropathy. In the other 8 patients, a kidney biopsy could not be performed due to clinical conditions that contraindicated the biopsy procedure. To assess the diagnosis of myeloma cast nephropathy in those patients without kidney biopsy the following criteria have to be fulfilled, according to the International Myeloma Working Group Recommendations: (a) past or new diagnosis of MM, (b) serum FLC measurement > 500 mg/L, (c) albuminuria to proteinuria ratio < 30%, and (d) persistence of AKI after the correction of precipitating factors (hypercalcemia, nephrotoxicity, dehydration) [19]. Two additional patients had the diagnosis of MM and AKI but the FLC levels were below the threshold of 500 mg/L. These two patients required renal replacement treatment so it was elected to initiate hemodiafiltration with ultrafiltrate regeneration assuming that this procedure offered more benefit to the patient that a simple hemodialysis procedure. Nevertheless these two patients were not analyzed as the rest of patients.

The procedure used to reduce the circulating levels of FLC was the hemodiafiltration with ultrafiltrate regeneration (Supra HFR) (Bellco©/Medtronic©). This technique combines convection, adsorption and diffusion; this is accomplished by two filters and a cartridge. The convection process takes place in the first filter, a Super High Flux polyphenylene membrane with a high cut-off and a 0.7 m2 surface. The generated ultrafiltrate (UF) circulates throughout a cartridge of adsorbent resin (Suprasorb, 80 ml) at a maximum flow rate of 70 ml/min, to remove the uremic toxins from the UF. The UF is subsequently reinfused before it reaches a second chamber containing a low permeability polyphenylene filter of 1.7 m2 surface, where the diffusion process takes place. A scheme of the procedure is shown in the Fig. 1.

Fig. 1
figure 1

Diagram of hemodiafiltration with regeneration of the ultrafiltrate by adsorption in resin. 1: High permeability filter (Convection). 2: Resin cartridge (Adsorption). 3: Low permeability filter (Diffusion). Protocol of samples extraction: The blood samples were obtained from the arterial port of the central venous catheter before (pre) (a) and immediately after (post) (b) the completion of the dialysis procedure (a total of 2 samples). Ultrafiltrate, pre (c) and post (d) resin, samples were taken at 5 min after starting the session (2 samples) and 5 min before the end of the session (2 samples). A total of six samples were collected during the procedure: 2 arterial blood samples and 4 samples of ultrafiltrate.

Full size image

Blood and dialysate flow were set at 300–350 and 500 ml/min respectively. The net ultrafiltration rate was programmed according to interdialysis weight gain. The dialysate calcium and potassium concentration were 3 and 2 mEq/L respectively. The volume of endogenous UF for each 4-h session was between 13.2–14.4 l. The number of hemodiafiltration with ultrafiltrate regeneration sessions was individually adjusted in each case. The duration of the 2 initial dialysis sessions was 150 and 180 min respectively, the remaining sessions 240 min three times a week. The first 2 dialysis sessions lasted only 150 and 180 min respectively because in the design of this observational study, a daily incremental dialysis dose (150, 180 and 240 min) was prescribed. Anticoagulation was achieved by initial bolus of heparin sodium and an hourly dose. A temporary catheter was placed as an initial vascular access and, after 2 weeks of treatment, it was replaced by a tunneled catheter. Treatment with hemodiafiltration with ultrafiltrate regeneration was extended while the patient required dialysis, even if the serum light chains levels were less than 500 mg/L.

Laboratory tests

Blood samples were obtained from the blood lines pre- and post- filters at the beginning and at the end of the procedure. Samples of UF were drawn before and after the resin cartridge, 5 min after the initiation and 5 min before the completion of the procedure (Fig. 1). The concentration of FLC and albumin were measured in each sample. The serum levels post-dialysis were corrected by the ultrafiltration rate in each case. The extractions were always obtained in the first weekly dialysis. The samples were stored until measurements of FLC below 500 mg/L were obtained.

Albumin was measured by the bromocresol purple colorimetric enzymatic method. The quantification of kappa and lambda FLC in blood and UF samples was performed with the Freelite kit (The Binding Site Group Ltd.) for use in the Siemens BN® II nephelometer; this is a test validated for renal failure patients [20]. The normal range is 3.3–19.4 mg/L for kappa and 5.71–26.3 mg/L for lambda.

The reduction ratio per session (RRs) was calculated as follows:

$$ \mathrm{RRs}=\left({\mathrm{C}}_{\mathrm{pre}}-{\mathrm{C}}_{\mathrm{post}-\mathrm{corr}}\right)/{\mathrm{C}}_{\mathrm{pre}}\times 100 $$

where Cpre is the pre-dialysis concentration and Cpost-corr is the post-dialysis concentration corrected for hemoconcentration according to the following formula:

$$ {\mathrm{C}}_{\mathrm{post}-\mathrm{corr}}={\mathrm{C}}_{\mathrm{post}}/\left(1+\left(\Delta \mathrm{BW}/\left(0.2\ \mathrm{x}\ {\mathrm{BW}}_{\mathrm{post}}\right)\right)\right) $$

where Cpost is the post-dialysis concentration without correction, ΔBW is the weight reduction during dialysis (ultrafiltration) and BWpost is the body weight post dialysis [21].

Statistical analysis

Continuous variables are shown as mean (± standard deviation, SD). Categorical variables are presented as percent (%). A p-value < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS statistical program (SPSS Inc., Chicago, IL, USA).

Results

There were nine patients with AKI secondary to MM included in the study. All patients were treated early after diagnosis, with hemodiafiltration and ultrafiltrate regeneration. Clinical and demographic characteristics are shown in Table 1. The AKI class for each patient according with AKIN classification is also shown in Table 1.

Table 1 Baseline demographics characteristics at the diagnosis of MM
Full size table

All patients were Caucasian (4 males and 5 females), mean age: 69.6 ± 9.5 years with a mean serum creatinine of 0.75 ± 0.26 mmol/L. The serum FLC levels were quantified at diagnosis: kappa FLC isotype was present in 5 patients (55.6%) and lambda FLC isotype in 4 patients (44.4%). The mean concentration of light chain kappa was 13,890 ± 9558 mg/L and the mean concentration of light chain lambda was 2262 ± 2452 mg/L. The initial levels of FLC and the mean percent reduction of FLC in each patient are listed in Tables 1 and 2. After 12 and 21 days from the beginning of chemotherapy and extracorporeal removal of FLC, the RR of FLC was 44.2–45.6% for kappa and 40.7–41.5% for lambda. The number of Supra HFR sessions performed for each patient during the first 3 months is shown in Table 2.

Table 2 Data on treatment and clinical evolution at first year
Full size table

Serum albumin concentration pre and post session were similar (0.43 ± 0.06 mmol/L pre vs. 0.42 ± 0.07 mmol/L post). Serum albumin levels were measured in 4 patients and in the two other patients. In the other 5 patients, this measurement was not performed due to practical problems. The FLC removal from the UF by the cartridge at the beginning of the procedure was 99.2% for kappa and 97.06% for lambda light chains; the uptake of albumin was trivial (0.7%). At the end the session the capacity of the cartridge to adsorb kappa light chain was still very significant (63.7%); and the ability to remove lambda light was still sizeable (33.6%). The loss of albumin remained very low at the end of the procedure (0.015%). Moreover, no complications associated with the technique were observed.

In 3 patients (33.3%) (patients 2, 3 and 4) the renal function improved after 2.75 ± 0.43 months of treatment and the mean creatinine decreased from 0.99 ± 0.18 mmol/L to 0.29 ± 0.14 mmol/L; then, it continued to decrease until the end of the follow up (Creatinine: 0.18 ± 0.04 mmol/L). Two patients (22.2%) died during the first year (patients 1 and 5) and 4 patients (44.4%) required maintenance dialysis (patients 6, 7, 8 and 9). Patients 9 and 11 did not complete 1 year of follow-up; patient 11 recovered renal function after 17 days of treatment. With respect to causes of deaths, patient 1, dependent on dialysis, died of septic shock 10 days after an autotransplant of hematopoietic cells (7.5 months after diagnosis of MM). Patient 5, who was also dependent on dialysis, died of septic shock at month 11. Patient 4 recovered renal function but died 7 months later due to a septicemia (his creatinine was 0.22 mmol/L); and patient 10, who was dependent on dialysis, committed suicide at month 16. Two patients died from septic shock due to respiratory infection. The tunneled catheter was not the source of the infection. Moreover, an arteriovenous fistula was created in patients who did not recover renal function after 3 months of treatment.

Discussion

The present study was performed in patients with AKI secondary to MM to evaluate the effectiveness of hemodiafiltration with ultrafiltrate regeneration in reducing FLC and to determine whether there is albumin loss with this procedure. Our results show that the hemodiafiltration with ultrafiltrate regeneration technique produces an effective and sustained removal of FLC, without a significant loss of albumin. Therefore, this technique is effective as an adjunctive treatment for MM in combination with chemotherapy allowing the renal recovery in 33.3% of patients.

To our knowledge, the present report is the largest series of multiple myeloma patients treated with hemodiafiltration with ultrafiltrate regeneration. There were 11 patients analyzed, which may be sufficient to estimate the percentage reduction of FLC. Kappa and lambda FLC have a molecular weight of 22.5 kD and 45 kD, respectively. Testa et al. showed that this technique removes FLC, particularly kappa, in patients with both monoclonal and polyclonal gammopathies [15]. The removal of FLC reported in other recent studies has been around 84% for kappa [22] and 32.2–49.5% [23] or 69.3% [22] for lambda chains. Although other groups have shown a reduction of serum FLC with hemodiafiltration with ultrafiltrate regeneration [22,23,24], our study is the first that analyzes the concentration of FLC and albumin in both, blood and ultrafiltrate. The FLC reduction ratio obtained in the ultrafiltrate was greater than in blood. It was demonstrated that albumin was not adsorbed by the resin cartridge and was reinfused before the second chamber. Thus, the Super High Flux with polyphenylene membrane allowed the passage of FLC (especially kappa), without loss of albumin. According to the cut off of this first filter, which is the limiting factor for the FLC’s blood extraction and on the basis of the dimeric composition of lambda chains, it can be assumed that in hemodiafiltration with ultrafiltrate regeneration the kappa chains extraction was twice than lambda. The membrane permeability for a solute mainly depends on the molecular weight and it is modified by the shape of the solute, ionic charge and hydrodynamic radius. The molecular weight cut-off is defined as the molecular weight where the sieving coefficient is 0.1 [25, 26]. Based on this definition and using the information previously reported it is assumed that the cut-off of Supra HFR is close to albumin molecular weight (60 kDa) since the sieving coefficient is 0.11. In fact, in our study a small amount of albumin was detected on the UF that was reinfused into the extracorporeal circuit, since it was nor adsorbed by the resin. This is the reason why the loss of albumin remained very low, only 0.015% at the end of the procedure. Therefore if the sieving coefficient of Supra HFR for albumin is 0.11, the permeability for lambda free light chain (molecular weight 45 KDa) should be high enough to produce an appreciable reduction in its serum concentration. Other authors have observed that the use of filters with limited cut-off is capable of reducing circulating levels of FLC. It has been reported that the HFR17 a filter with a cut-off of 35 KDa was able to reduce serum levels of lambda light chains by 30.3 ± 2.9% [21].

The polymethylmethacrylate (PMMA) membranes have obtained satisfactory results in terms of light chain removal [27], but the adsorption process is limited by the saturation of the membrane. Standard PMMA hemodialysis (PMMA membrane BK 2.1 m2 Toray®) was compared with an enhanced adsorption dialysis, which involves PMMA dialyzer replacement after 2 h. The reduction of FLC was greater in enhanced adsorption than standard PMMA dialysis: 31% for kappa and 53% for lambda vs. 22% for kappa and 21% for lambda. Thus, to maintain FLC reduction and avoid membrane saturation, it is required to replace the dialyzer during the session [28].

The HCO membranes have a large pore (cut-off of 45–60 kD), allowing the filtration of both FLC [5, 29, 30]. The removal of FLC with HCO membrane is 66–69% of kappa and 71–90% of lambda [8, 31]. The procedure is more effective if applied promptly after an early diagnosis and treatment of the MM [5, 32]. Hutchison et al. showed that the factors which predicted non need of further dialysis were the degree of FLC reduction at days 12 and 21 as well as the time to initiating HCO-HD [9]. Moreover, Sens et al. reported a significant recovery of renal function if the FLC reduction rate was > 75% after 12 days of the initiation of chemotherapy and PMMA [33]. After 12 and 21 days from the beginning of chemotherapy and extracorporeal removal of FLC, the RR of FLC was 44.2 to 45.6% for kappa and 40.7 to 41.5% for lambda; with this reduction in FLC 33.3% recovered renal function and 44.4% required maintenance dialysis at the end of follow-up. Furthermore, in a recent randomized clinical trial involving 98 patients with myeloma cast nephropathy on chemotherapy, the use of HCO hemodialysis compared with conventional hemodialysis did not result in a significant benefit with respect to hemodialysis dependence at 3 months [12]. Later, Hutchison et al. shown that HCO hemodialysis was not associated with an improvement in renal recovery as compared with to High Flux- hemodialysis in patients with a new diagnosis of MM and myeloma cast nephropathy who received modified-dose bortezomib-containing chemotherapy although in both groups there was a sustained early reduction in serum FLC levels [13].

Other advantages of the hemodiafiltration with ultrafiltrate regeneration are: First, there was no decrease of albumin in blood and there was no adsorption of albumin to the resin; thus, albumin replacement is not required. That is a relevant advantage of this technique because combine hemodialysis with apheresis in a unique session of reasonable length, without the need for albumin replacement and the potential loss of other proteins of the immune system with a danger of infectious complications in subjects at a high risk due to the background haematologic disease. Second, in addition to avoiding further deposition of FLC to reduce the renal toxicity burden, it allows a rapid clearance of FLC that can be harmful elsewhere outside of the kidney, particularly amyloidogenic lambda chains for the heart. Third, there were no complications associated with the technique. It should be noticed that only 22.2% of the patients died during the first year and the cause of death was septic shock secondary to comorbidities associated to MM itself or its treatment (infections, immunosuppression, autotransplantation of hematopoietic cells and others); another two patients also died during the follow-up, so total mortality during the entire follow-up was 33.3% (patients 1, 4 and 5). Others have reported an increased mortality during the first year in MM patients undergoing hemodialysis treatment [34]. Yadav et al. shown that the median time to death in these patients was 5.1 months [35]. It is important to highlight that an early initiation of hemodialysis and prompt hemodialysis may improve the outcome [34].

In our study, renal recovery was achieved in two patients with kappa MM and in one patient with lambda MM. In a single-center study, renal recovery was associated with effective treatment of MM and a sustained reduction in the concentration of the involved FLC clone. The majority of patients who recover renal function have no further need for dialysis [35]. It has been described that the median overall survival in people who recovered renal function was 62.4 [36] – 64.1 [35] months. Joseph et al. recently published that renal recovery is inversely associated with more aggressive malignancies, with a worse proteinuria and with a history of high-dose therapy combined with autologous stem cell transplantation [3]. The published data on renal recovery using PMMA is not uniform. Sens et al. showed that an intensive hemodialysis with PMMA (6 h session requiring two PMMA filters (BK-F 2.1 m2 dialyzers) per session) resulted in a high rate of renal recovery (71%) and survival (62% alive at 24 months) [33]. However, Hudier et al. after intensive hemodialysis with PMMA, but using only one filter per session, did not observed a clear benefit on renal function as compared with standard PMMA hemodialysis; renal recovery rate was 38% after intensive hemodialysis as compared with 35% in patients receiving standard hemodialysis [37]. Therefore, hemodiafiltration with ultrafiltrate regeneration achieves a greater and maintained reduction of FLC and has promising results on renal recovery as compared to other adsorptive techniques (PMMA).

Conclusions

In conclusion, hemodiafiltration with ultrafiltrate regeneration is a safe technique and provides a significant and sustained reduction of FLC in patients with AKI secondary to MM. The adsorptive capacity is maintained throughout the session and there is no loss of albumin. If hemodiafiltration with ultrafiltrate regeneration is used early in combination with effective chemotherapy, renal recovery is significant, regardless of the predominant type of light chains.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

AKI:

Acute Kidney Injury

FLC:

Free light chains

HCO:

High-Cut-Off

Supra HFR:

Hemodiafiltration with ultrafiltrate regeneration

MM:

Multiple myeloma

PMMA:

Polymethylmethacrylate

RRs:

Reduction ratio per session

UF:

Ultrafiltrate

References

  1. Sanders PW, Booker BB. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest. 1992;89:630–9.

    Article  CAS  Google Scholar 

  2. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic myeloma study group. Eur J Haematol. 2000;65:175–81.

    Article  CAS  Google Scholar 

  3. Joseph A, Harel S, Venot M, Valade S, Mariotte E, Pichereau C, et al. Renal recovery after severe acute kidney injury in critically ill myeloma patients: a retrospective study. Clin Kidney J. 2018;11(1):20–5.

    Article  Google Scholar 

  4. Darmon M, Ciroldi M, Thiery G, Schlemmer B, Azoulay E. Clinical review: specific aspects of acute renal failure in cancer patients. Crit Care. 2006;10:211–8.

    Article  Google Scholar 

  5. Khalafallah A, Wuong S, Love S, Mohamed M, Mace R, Khalil R, et al. Early application of high cut-off Haemodialysis for de-novo myeloma nephropathy is associated with long-term dialysis-independency and renal recovery. Mediterr J Hematol Infect Dis. 2013;5:e2013007.

    Article  Google Scholar 

  6. Hutchison CA, Cockwell P, Reid S, Chandler K, Mead G, Harrison J, et al. Efficient removal of inmunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007;18:886–95.

    Article  CAS  Google Scholar 

  7. Viaene L, Annaert P, de Loor H, Poesen R, Evenepoel P, Meijers B. Albumin is the main plasma binding protein for indoxyl sulfate and p-cresyl sulfate. Biopharm Drug Dispos. 2013;34(3):165–75.

    Article  CAS  Google Scholar 

  8. Hutchison CA, Bradwell A, Cook M, Basnayake K, Basu S, Harding S, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009;4:745–54.

    Article  CAS  Google Scholar 

  9. Hutchison CA, Heyne N, Airia P, Schindler R, Zickler D, Cook M, et al. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant. 2012;27:3823–8.

    Article  CAS  Google Scholar 

  10. Gerth HU, Pohlen M, Görlich D, Thölking G, Kropff M, Berdel WE, et al. Impact of high-cut-off dialysis on renal recovery in dialysis-dependent multiple myeloma patients: results from a case-control study. PLoS One. 2016;11(5):e0154993.

    Article  Google Scholar 

  11. Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011;22:1129–36.

    Article  CAS  Google Scholar 

  12. Bridoux F, Carron PL, Pegourie B, Alamartine E, Augeul-Meunier K, Karras A, et al. For the MYRE study group. Effect of high-cut-off hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy. JAMA. 2017;318(21):2099–110.

    Article  Google Scholar 

  13. Hutchison CA, Cockwell P, Moroz V, Bradwell AR, Fifer L, Gillmore JD, et al. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. Lancet Haematol. 2019;6(4):e217–28.

    Article  Google Scholar 

  14. Esquivias-Motta E, Martín-Malo A, Buendia P, Álvarez-Lara MA, Soriano S, Crespo R, et al. Hemodiafiltration with endogenous reinfusion improved microinflammation and endothelial damage compared with online-hemodiafiltration: a hypothesis generating study. Artif Organs. 2017;41(1):88–98.

    Article  CAS  Google Scholar 

  15. Testa A, Dejoie T, Lecarrer D, Wratten M, Sereni L, Renaux JL. Reduction of free immunoglobulin light chains using adsorption properties of hemodiafiltration with endogenous reinfusion. Blood Purif. 2010;30:34–6.

    Article  CAS  Google Scholar 

  16. Pendón-Ruiz de Mier MV, Álvarez-Lara MA, Ojeda-López R, Martín-Malo A, Carracedo J, Caballero-Villarraso J, et al. Effectiveness of hemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure. Nefrología. 2013;33(6):788–96.

    PubMed  Google Scholar 

  17. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.

    Article  Google Scholar 

  18. Leung N, Gertz MA, Zeldenrust SR, Rasjkumar SV, Dispenzieri A, Fervenza FC, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008;73:1282–8.

    Article  CAS  Google Scholar 

  19. Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34:1544–57.

    Article  Google Scholar 

  20. Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol. 2008;9:11–9.

    Article  Google Scholar 

  21. Donati G, Moretti MI, Baraldi O, Spazzoli A, Capelli I, Comai G, et al. Removal of free light chains in hemodialysis patients without multiple myeloma: a crossover comparison of three different dialyzers. BMC Nephrol. 2016;17(1):193–202.

    Article  Google Scholar 

  22. Menè P, Giammarioli E, Fofi C, Antolino G, La Verde G, Tafuri A, et al. Serum free light chains removal by HFR hemodiafiltration in patients with multiple myeloma and acute kidney injury: a case series. Kidney Blood Press Res. 2018;43:1263–72.

    Article  Google Scholar 

  23. Li Cavoli G, Passanante S, Schillaci O, Servillo F, Zagarrigo C, Li Cavoli TV, et al. Haemodiafiltration with ultrafiltrate regeneration in the removal of free light chains in multiple myeloma and acute kidney injury. Nefrología. 2018;38(3):337–8.

    Article  Google Scholar 

  24. Pasquali S, Iannuzzella F, Corradini M, Mattei S, Bovino A, Stefani A, et al. A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR). J Nephrol. 2015;28:251–4.

    Article  CAS  Google Scholar 

  25. Cuoghi A, Caiazzo M, Morani E, Bellei E, Bergamini S, Sereni L, et al. New horizon in dialysis depuration: characterization of a polysulfone membrane able to break the 'albumin wall'. J Biomater Appl. 2015;29(10):1363–71.

    Article  CAS  Google Scholar 

  26. Boschetti-de-Fierro A, Voigt M, Storr M, Krause B. Extended characterization of a new class of membranes for blood purification: the high cut-off membranes. Int J Artif Organs. 2013;36(7):455–63.

    Article  Google Scholar 

  27. Santoro A, Grazia M, Mancini E. The double polymethylmethacrylate filter (DELETE system) in the removal of light chains in chronic dialysis patients with multiple myeloma. Blood Purif. 2013;35(suppl 2):5–13.

    Article  CAS  Google Scholar 

  28. Fabbrini P, Sirtori S, Casiraghi E, Pieruzzi F, Genovesi S, Corti D, et al. Polymethylmethacrylate membrane and serum free light chain removal: enhancing adsorption properties. Blood Purif. 2013;35(suppl 2):52–8.

    Article  CAS  Google Scholar 

  29. Basnayake K, Hutchison CA, Kamel D, Sheaff M, Ashman N, Cook M, et al. Resolution of cast nephropathy following free light chain removal by haemodialysis in a patient with multiple myeloma: a case report. J Med Case Rep. 2008;2:380–5.

    Article  Google Scholar 

  30. Hutchison CA, Harding S, Mead G, Goehl H, Storr M, Bradwell A, et al. Serum free-light chain removal by high cut-off haemodialysis: optimizing removal and supportive care. Artif Organs. 2008;32:910–7.

    Article  Google Scholar 

  31. Martín-Reyes G, Toledo-Rojas R, Torres-de Rueda A, Sola-Moyano E, Blanca-Martos L, Fuentes-Sánchez L, et al. Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma. Nefrología. 2012;32(1):35–43.

    PubMed  Google Scholar 

  32. Gaballa MR, Laubach JP, Schlossman RL, Redman K, Noonan K, Mitsiades CS, et al. Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012;5:51–66.

    Article  CAS  Google Scholar 

  33. Sens F, Chaintreuil D, Jolivot A, Guebre-Egziabher F, Robinson P, Karlin L, et al. Effectiveness of IHD with adsorptive PMMA membrane in myeloma cast nephropathy: a cohort study. Am J Nephrol. 2017;46:355–63.

    Article  CAS  Google Scholar 

  34. Chang CF, Chien WC, Chung CH, Lee JC, Hsu SN, Chen JH. Impact of hemodialysis on the prognosis of multiple myeloma: a nationwide population-based study and single-institute analysis. Oncol Lett. 2018;16(2):1991–2002.

    PubMed  PubMed Central  Google Scholar 

  35. Yadav P, Hutchison CA, Basnayake K, Stringer S, Jesky M, Fifer L, et al. Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury. Eur J Haematol. 2016;96(6):610–7.

    Article  Google Scholar 

  36. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–8.

    Article  CAS  Google Scholar 

  37. Hudier L, Decauz O, Haddj-Elmrabet A, Lino M, Mandart L, Siohan P, et al. Intensive haemodialysis using PMMA dialyser does not increase renal response rate in multiple myeloma patients with acute kidney injury. Clin Kidney J. 2018;11(2):230–5.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Nephrology Service, Reina Sofia University Hospital, Avenida Menéndez Pidal S/N, 14004, Córdoba, Spain

    M. Victoria Pendón-Ruiz de Mier, Raquel Ojeda, Sagrario Soriano, Mariano Rodríguez & Alejandro Martín-Malo

  2. Research Unit, Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain

    M. Victoria Pendón-Ruiz de Mier, Ana Navas, Corona Alonso, Javier Caballero-Villarraso, Pedro Aljama, Sagrario Soriano, Mariano Rodríguez & Alejandro Martín-Malo

  3. University of Cordoba, Cordoba, Spain

    M. Victoria Pendón-Ruiz de Mier, Ana Navas, Corona Alonso, Javier Caballero-Villarraso, Pedro Aljama, Sagrario Soriano, Mariano Rodríguez & Alejandro Martín-Malo

  4. Spanish Renal Research Network (REDinREN), Institute of Health Carlos III, Madrid, Spain

    M. Victoria Pendón-Ruiz de Mier, Pedro Aljama, Sagrario Soriano, Mariano Rodríguez & Alejandro Martín-Malo

  5. Quality Service, Reina Sofia University Hospital, Cordoba, Spain

    M. Antonia Álvarez-Lara

  6. Immunology Service, Reina Sofia University Hospital, Cordoba, Spain

    Ana Navas & Corona Alonso

  7. Clinical Analysis Service, Reina Sofia University Hospital, Cordoba, Spain

    Javier Caballero-Villarraso

  8. Hematology Service, Reina Sofia University Hospital, Cordoba, Spain

    Miguel A. Álvarez

Authors
  1. M. Victoria Pendón-Ruiz de Mier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raquel Ojeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Antonia Álvarez-Lara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ana Navas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Corona Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Javier Caballero-Villarraso
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pedro Aljama
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Miguel A. Álvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sagrario Soriano
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mariano Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Alejandro Martín-Malo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MVPRM, RO, PA and AMM conceived and designed the work. MVPRM, MAAL, AN, CA, JCV and MAA performed substantial contributions to the acquisition and analysis of data for the work. MVPRM, RO, PA, SS, MR and AMM interpreted the data for the work. All authors have participated in drafting the work or revising it critically, have done a final approval of the version to be published and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Corresponding author

Correspondence to M. Victoria Pendón-Ruiz de Mier.

Ethics declarations

Ethics approval and consent to participate

The research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. Subjects have given their written informed consent prior to their inclusion in the study and the study protocol was approved by the institute’s committee on human research “Cordoba Research Ethics Committee (Reina Sofia University Hospital, Cordoba, Spain.)” (Record number: 288, committee’s reference number: 4334).

Consent for publication

Not applicable.

Competing interests

MAA reports grants, personal fees and non-financial support from Celgene, personal fees from Amgen, personal fees from Janssen, outside the submitted work; and AMM reports personal fees from Vifor pharma, personal fees from Medtronic, outside the submitted work. Rest of authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pendón-Ruiz de Mier, M., Ojeda, R., Álvarez-Lara, M.A. et al. Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients. BMC Nephrol 21, 227 (2020). https://doi.org/10.1186/s12882-020-01885-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12882-020-01885-8

Keywords

BMC Nephrology

ISSN: 1471-2369

Contact us